Skin rash could predict the response to EGFR tyrosine kinase inhibitor and the prognosis for patients with non-small cell lung cancer: a systematic review and meta-analysis.

<h4>Background</h4>The aim of this study was to assess the role of skin rash in predicting the efficacy of epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) and the prognosis of patients with non-small cell lung cancer (NSCLC).<h4>Method</h4>We systemati...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Hong-bing Liu, Ying Wu, Tang-feng Lv, Yan-wen Yao, Yong-ying Xiao, Dong-mei Yuan, Yong Song
Formato:	article
Lenguaje:	EN
Publicado:	Public Library of Science (PLoS) 2013
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/98f5613a8b274eb4a0bafbfcb0dafa00
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:98f5613a8b274eb4a0bafbfcb0dafa00
record_format	dspace
spelling	oai:doaj.org-article:98f5613a8b274eb4a0bafbfcb0dafa002021-11-18T07:59:27ZSkin rash could predict the response to EGFR tyrosine kinase inhibitor and the prognosis for patients with non-small cell lung cancer: a systematic review and meta-analysis.1932-620310.1371/journal.pone.0055128https://doaj.org/article/98f5613a8b274eb4a0bafbfcb0dafa002013-01-01T00:00:00Zhttps://www.ncbi.nlm.nih.gov/pmc/articles/pmid/23383079/?tool=EBIhttps://doaj.org/toc/1932-6203<h4>Background</h4>The aim of this study was to assess the role of skin rash in predicting the efficacy of epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) and the prognosis of patients with non-small cell lung cancer (NSCLC).<h4>Method</h4>We systematically searched for eligible articles investigating the association between rash and the efficacy of EGFR-TKIs and the prognosis of patients with NSCLC. The summary risk ratio (RR) and hazard ratio (HR) were calculated using meta-analysis.<h4>Results</h4>We identified 33 eligible trials involving 6,798 patients. We used two different standards to group the patients [standard 1: rash vs. no rash, standard 2: rash (≥ stage 2) vs. rash (stage 0, 1)]. For standard 1, the objective response rate (ORR) and disease control rate (DCR) of the rash group were significantly higher than the no rash group [RR = 3.28; 95% CI: 2.41-4.47(corrected RR = 2.225, 95% CI: 1.658-2.986); RR = 1.96, 95% CI: 1.58-2.43]. The same results were observed for standard 2. For standards 1 and 2, the progression-free survival (PFS) (HR = 0.45, 95% CI: 0.37-0.53; HR = 0.57, 95% CI: 0.50-0.65) and overall survival (OS) (HR = 0.40, 95% CI: 0.28-0.52; HR = 0.53, 95% CI: 0.35-0.71) of the rash group were significantly longer than the control group, and the same results were observed in the subgroup analysis.<h4>Conclusions</h4>skin rash after EGFR-TKI treatment may be an efficient clinical marker for predicting the response of patients with NSCLC to EGFR-TKIs. Furthermore, skin rash is also the prognostic factor of patients with NSCLC. Patients with skin rash have a longer PFS and OS.Hong-bing LiuYing WuTang-feng LvYan-wen YaoYong-ying XiaoDong-mei YuanYong SongPublic Library of Science (PLoS)articleMedicineRScienceQENPLoS ONE, Vol 8, Iss 1, p e55128 (2013)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Hong-bing Liu Ying Wu Tang-feng Lv Yan-wen Yao Yong-ying Xiao Dong-mei Yuan Yong Song Skin rash could predict the response to EGFR tyrosine kinase inhibitor and the prognosis for patients with non-small cell lung cancer: a systematic review and meta-analysis.
description	<h4>Background</h4>The aim of this study was to assess the role of skin rash in predicting the efficacy of epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) and the prognosis of patients with non-small cell lung cancer (NSCLC).<h4>Method</h4>We systematically searched for eligible articles investigating the association between rash and the efficacy of EGFR-TKIs and the prognosis of patients with NSCLC. The summary risk ratio (RR) and hazard ratio (HR) were calculated using meta-analysis.<h4>Results</h4>We identified 33 eligible trials involving 6,798 patients. We used two different standards to group the patients [standard 1: rash vs. no rash, standard 2: rash (≥ stage 2) vs. rash (stage 0, 1)]. For standard 1, the objective response rate (ORR) and disease control rate (DCR) of the rash group were significantly higher than the no rash group [RR = 3.28; 95% CI: 2.41-4.47(corrected RR = 2.225, 95% CI: 1.658-2.986); RR = 1.96, 95% CI: 1.58-2.43]. The same results were observed for standard 2. For standards 1 and 2, the progression-free survival (PFS) (HR = 0.45, 95% CI: 0.37-0.53; HR = 0.57, 95% CI: 0.50-0.65) and overall survival (OS) (HR = 0.40, 95% CI: 0.28-0.52; HR = 0.53, 95% CI: 0.35-0.71) of the rash group were significantly longer than the control group, and the same results were observed in the subgroup analysis.<h4>Conclusions</h4>skin rash after EGFR-TKI treatment may be an efficient clinical marker for predicting the response of patients with NSCLC to EGFR-TKIs. Furthermore, skin rash is also the prognostic factor of patients with NSCLC. Patients with skin rash have a longer PFS and OS.
format	article
author	Hong-bing Liu Ying Wu Tang-feng Lv Yan-wen Yao Yong-ying Xiao Dong-mei Yuan Yong Song
author_facet	Hong-bing Liu Ying Wu Tang-feng Lv Yan-wen Yao Yong-ying Xiao Dong-mei Yuan Yong Song
author_sort	Hong-bing Liu
title	Skin rash could predict the response to EGFR tyrosine kinase inhibitor and the prognosis for patients with non-small cell lung cancer: a systematic review and meta-analysis.
title_short	Skin rash could predict the response to EGFR tyrosine kinase inhibitor and the prognosis for patients with non-small cell lung cancer: a systematic review and meta-analysis.
title_full	Skin rash could predict the response to EGFR tyrosine kinase inhibitor and the prognosis for patients with non-small cell lung cancer: a systematic review and meta-analysis.
title_fullStr	Skin rash could predict the response to EGFR tyrosine kinase inhibitor and the prognosis for patients with non-small cell lung cancer: a systematic review and meta-analysis.
title_full_unstemmed	Skin rash could predict the response to EGFR tyrosine kinase inhibitor and the prognosis for patients with non-small cell lung cancer: a systematic review and meta-analysis.
title_sort	skin rash could predict the response to egfr tyrosine kinase inhibitor and the prognosis for patients with non-small cell lung cancer: a systematic review and meta-analysis.
publisher	Public Library of Science (PLoS)
publishDate	2013
url	https://doaj.org/article/98f5613a8b274eb4a0bafbfcb0dafa00
work_keys_str_mv	AT hongbingliu skinrashcouldpredicttheresponsetoegfrtyrosinekinaseinhibitorandtheprognosisforpatientswithnonsmallcelllungcancerasystematicreviewandmetaanalysis AT yingwu skinrashcouldpredicttheresponsetoegfrtyrosinekinaseinhibitorandtheprognosisforpatientswithnonsmallcelllungcancerasystematicreviewandmetaanalysis AT tangfenglv skinrashcouldpredicttheresponsetoegfrtyrosinekinaseinhibitorandtheprognosisforpatientswithnonsmallcelllungcancerasystematicreviewandmetaanalysis AT yanwenyao skinrashcouldpredicttheresponsetoegfrtyrosinekinaseinhibitorandtheprognosisforpatientswithnonsmallcelllungcancerasystematicreviewandmetaanalysis AT yongyingxiao skinrashcouldpredicttheresponsetoegfrtyrosinekinaseinhibitorandtheprognosisforpatientswithnonsmallcelllungcancerasystematicreviewandmetaanalysis AT dongmeiyuan skinrashcouldpredicttheresponsetoegfrtyrosinekinaseinhibitorandtheprognosisforpatientswithnonsmallcelllungcancerasystematicreviewandmetaanalysis AT yongsong skinrashcouldpredicttheresponsetoegfrtyrosinekinaseinhibitorandtheprognosisforpatientswithnonsmallcelllungcancerasystematicreviewandmetaanalysis
_version_	1718422683452964864

Skin rash could predict the response to EGFR tyrosine kinase inhibitor and the prognosis for patients with non-small cell lung cancer: a systematic review and meta-analysis.

Ejemplares similares